Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
暂无分享,去创建一个
A. Hauschild | M. Ross | I. Puzanov | C. Garbe | P. Friedlander | C. Lebbé | Parminder Singh | M. Milhem | H. Kaufman | O. Hamid | J. Glaspy | F. Collichio | J. Chesney | R. Andtbacka | J. Gansert | T. Logan | Jenny J. Kim | Lisa Chen